Form 4: Bolt Biotherapeutics Director Acquires Stock Options

Jakob Dupont, a Director at Bolt Biotherapeutics, acquired 5,000 stock options with an exercise price of $4.43.

Summary

• Jakob Dupont, a Director at Bolt Biotherapeutics, Inc., acquired 5,000 stock options on June 10, 2026.
• The stock options have an exercise price of $4.43 per share.
• These options are for the company's Common Stock.
• The options are set to expire on June 9, 2036.
• The shares subject to the option will vest on the earlier of June 9, 2027, or the day prior to the next annual stockholder meeting, contingent on continuous service.
• Vesting will accelerate to full upon a change in control of the Issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard grant of stock options to a director, which is typical for incentivizing performance and retention in the biotech industry.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule and change-in-control acceleration provide incentives for long-term commitment and align with shareholder interests during potential acquisition scenarios.

Risks

• The value of the stock options is directly tied to the future performance of Bolt Biotherapeutics' stock price.
• If the company's stock price does not exceed the exercise price of $4.43, the options may not be profitable.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and potential change in control events. Vesting is tied to service and specific future dates.

Management Comments

• The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

Industry Context

StockSavvy.ai notes that insider grants of stock options are common in the biotechnology sector as a means to attract and retain key talent and align their interests with shareholders, especially in companies with long development cycles and inherent volatility.

Stakeholder Impact

• Shareholders: The grant of options to a director is a standard practice that can align management interests with shareholder value creation. The exercise price and vesting schedule will influence potential dilution and the director's incentive to drive stock price appreciation.
• Employees: While not directly impacting all employees, such grants can be part of a broader compensation strategy that aims to retain key personnel.
• Management: The options provide a financial incentive for the director to perform well and contribute to the company's success.

Next Steps

• Continuous service by Jakob Dupont through the vesting dates.
• Monitoring of Bolt Biotherapeutics' stock performance.
• Potential vesting acceleration upon a change in control.

Key Dates

Keywords

Bolt Biotherapeutics, BOLT, Form 4, Stock Options, Insider Trading, Director, Equity, SEC Filing